Clinical Trial Detail

NCT ID NCT03406858
Title Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Barbara Ann Karmanos Cancer Institute
Indications

prostate adenocarcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.